GSK Drug Shows Strong Liver Results in Phase 2

Once-monthly efimosfermin improved fibrosis and MASH resolution versus placebo in a 24-week phase 2 trial presented at The Liver Meeting 2026.

Updated on Nov. 17, 2026 in Weight Loss

Bold vector editorial illustration of a plain injection device beside a smooth abstract liver-shaped form on cream, in coral and teal.
GSK's once-monthly liver drug efimosfermin improved fibrosis in 45% of patients versus 21% on placebo in a 24-week phase 2 trial. AI Illustration. Upload story photo >

GSK presented phase 2 data for efimosfermin, an investigational once-monthly injection, at The Liver Meeting 2026 in Denver. In a 24-week randomized, placebo-controlled trial, 45% of patients on efimosfermin achieved fibrosis improvement versus 21% on placebo.

Why it matters

Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease, and a monthly treatment could offer a more convenient option if phase 3 results hold. Efimosfermin is already being evaluated in the phase 3 ZENITH and NEBULA trials.

In a 24-week phase 2 trial, 68% of patients on efimosfermin achieved MASH resolution versus 29% on placebo, with adverse events in 67% of treated patients versus 55% on placebo. Whether these benefits persist and how safety compares over longer periods remains to be shown in phase 3 studies.

The players

GSK

A global pharmaceutical company developing efimosfermin for MASH.

The details

Efimosfermin is a long-acting variant of fibroblast growth factor 21 (FGF21) given as a once-monthly subcutaneous injection. In an open-label cohort of 39 patients, 15 had compensated cirrhosis, and liver stiffness and other markers declined through 52 weeks, including in those with cirrhosis.

Timeline

  1. February 2026: The Lancet published the 24-week phase 2 trial results.

  2. November 5-9, 2026: The Liver Meeting 2026 was held in Denver, Colorado.

Health Landscape

Efimosfermin is a long-acting FGF21 analog being developed for MASH, a condition that has lacked approved treatments until recently. Its monthly dosing schedule would differ from the daily oral and weekly injectable options now in development for the same disease.

If approved, a once-monthly injection could reduce treatment frequency compared with more frequent dosing options. Patients should discuss any future MASH therapy with a clinician, since side effects were reported more often on the drug than on placebo in the trial.

The takeaway

Liver disease treatments are advancing toward less frequent dosing, but phase 3 results will determine whether early trial benefits hold up. Readers managing liver or metabolic health should follow outcomes from larger studies before expecting changes in care.

What happens next

Phase 3 results from the ZENITH and NEBULA trials of efimosfermin are expected in future regulatory discussions.

Further reading

Explore more on Weight Loss treatments and metabolic health research.

Source note: This article includes information reported by BioPharm International.